The maximum and minimum restoring forces are analytically derived, which can be used to predict the critical
switching current dependence on the magnetic configuration combinations of vortices. (C) 2011 American Institute of Physics. [doi:10.1063/1.3590333]“
“Introduction Carcinoid tumors are uncommon neoplasms in the diffuse peripheral endocrine system. Ovarian carcinoids are rare and can be primary or transplanted. Primary ovarian carcinoids make up approximately 0.5-1.7% of all carcinoid tumors.
Case report We describe the case of a 55-year-old Danusertib inhibitor female patient. A tumor in her right ovary was discovered during a regular examination. She had no significant clinical symptoms, but a pelvic ultrasound revealed a solid mass measuring 6.2 x 5.2 x 3.5 cm located in the right ovarian lobe. Serum AFP, CA199, CA125 and CEA levels were all within normal limits, as were serum E2, FSH and Prog hormone levels. The patient underwent a total hysterectomy and bilateral salpingo-oophorectomy. The right ovary and tumor were separated into two parts by the gynecologist. They were 4.0 x 3.1 x 2.5 cm and 3.2 x 2.0 x 1.1 cm in size, respectively. The tumor was totally solid and had a yellowish color and a smooth surface. There were no teratomatous components seen in the mass. Multiple sections
showed that the tumor was a total epithelial FG-4592 ic50 neoplasia with a trabecular structure surrounded by dense connective tissue. The tumor cells had abundant granular cytoplasms. Silver staining
showed neuroendocrine granules, and reticulin staining showed that tumor cells were arranged in a trabecular structure. The immunohistochemical study revealed a neuroendocrine origin with strong positivity for NSE, CgA and Syn. Other markers, such as a-inhibin and Calretinin, were negtive. Finally, the case was diagnosed as a primary ovarian trabecular carcinoid tumor.
Conclusion Primary ovarian trabecular carcinoid tumors are very rare. The patients lack clinical indicators, and final diagnosis depends on pathological examination, special staining and inmmunohistochemistry staining to confirm the neuroendocrine differentiation.”
“Forty-five consecutive subjects (26M, 19F; mean age 54 +/- 14 yrs) with a diagnosed retinal vein occlusion (RVO), were followed-up for 8 yrs. As many as 145 sex-age-and blood pressure-matched individuals MLN0128 clinical trial (78M, 67F; mean age 54.4 +/- 13.5 yrs), that did not experience any vascular event, served as controls. At the time of the RVO, controls and subjects did not differ as to hypercholesterolemia, hypertrigliceridemia, diabetes mellitus, smoking habits, inherited/acquired thrombophilia. At the follow-up completion, they differed as to statin consumption (p = 0.016). During the 8-yrs follow-up, in the control population, 11 out of 145 (7.6%) subjects had experienced a major vascular event (8 coronary artery disease; 3 cerebral non-fatal ischemic stroke).